Cellectis has 18 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile.
Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune system to target and eradicate cancers. Unlike autologous CAR-T immunotherapies that require a custom immunotherapy product for each patient, Cellectis uses gene editing to create cost-effective, "off-the-shelf" (allogeneic) products (UCART) from healthy donors that can be immediately available for patients across all geographies. What’s more, for patients without enough T-cells for autologous CAR T therapy, Cellectis can create T-cells based on patients’ own T-cells.
Cellectis has 18 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile. This enables us to develop a new generation of immunotherapy product candidates with additional safety and efficacy attributes designed to prevent them from attacking healthy tissues, and equip them to resist mechanisms that inhibit immune system activity. And unlike autologous treatments that use the patient’s own T-cells – which get progressively weaker with each round of chemotherapy – Cellectis' allogeneic cells remain strong.
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Alternext market of Euronext (ticker: ALCLS).
TALEN® is a registered trademark owned by Cellectis.
Here are some of our milestones
1999: Cellectis is founded
In 2000, Institut Pasteur grants exclusive rights on 9 patent families, including several based on André Choulika’s research, genesis of the gene editing field.
2005: Breakthrough: Cellectis enables the industrial production of nucleases
Cellectis research teams provide proof of the in vivo efficacy of meganucleases, the molecular "scissors" that enable us to precisely reprogram the genome of any living organism as needed – be it human, animal, vegetable, bacterium, or virus. Gene editing is born, and with it the possibility to industrialize a once unpredictable, predominantly manual science. A tremendous leap forward for researchers, pharmaceutical laboratories, and seed producers alike.
2007: Listing on the Alternext market of Euronext in Paris
With its impressive patent portfolio and enormous potential for growth, Cellectis makes a successful initial public offering on the Alternext market of Euronext in Paris (21.2 million Euros).
2008 – 2010: Acquisition of technologies and establishment of subsidiaries
2010: Acquisition of all assets of CytoPulse Inc., based in Maryland
The acquisition included Hybrimune electrofusion technology and PulseAgile technology for RNA transfection by electroporation. PulseAgile is now the standard technology for RNA transfection of T-cells.
2010: Founding of Cellectis plant sciences, Inc. (now Calyxt, Inc.)
2011: TAL nucleases patents are exclusively licensed to Cellectis by the University of Minnesota
2014: Strategic collaboration agreement with Servier
In February, Cellectis and Servier announce collaboration in allogeneic cell therapy to develop and commercialize novel product candidates targeting leukemia and other potential tumors.
2014: Global strategic cancer immunotherapy collaboration with Pfizer
In June, Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration to develop immunotherapies against selected targets in the field of oncology.
2015: Listing on the Nasdaq Global market in New York
With its unique capability to create allogeneic CAR T-cells from healthy donors rather than from the patients themselves, Cellectis makes the second largest IPO in the CAR T space with a total of 228.250 million USD.
2015: Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia with Weill Cornell Medical College
In June, Weill Cornell Medical College and Cellectis enter into a strategic translational research alliance to accelerate the development of a targeted immunotherapy for patients with acute myelogenous leukemia (AML).
2015: Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy with MD Anderson Cancer Center
In September, Cellectis and The University of Texas MD Anderson Cancer Center enter into a research and development alliance aimed at bringing novel cellular immunotherapies to patients suffering from different types of liquid tumors.
2015: First-in-man compassionate use of UCART19 for acute lymphoblastic leukemia (ALL)
In November, Cellectis announced that Great Ormond Street Hospital (GOSH) and University College London (UCL) will present encouraging data from a first in man clinical use of UCART19, at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando during the poster session.
2015: Cellectis files the first Clinical Trial Application for UCART19, an allogeneic gene edited CAR T-cell product candidate for hematological malignancies
Cellectis announced the submission of a clinical trial application (CTA) to the Medicines & Healthcare products Regulatory Agency (MHRA) requesting approval to initiate UCART19 First-in-Human clinical investigation in leukemia in the United Kingdom.
2016: Ongoing clinical trials of UCART19
Two ongoing clinical studies of UCART19 product candidate have started in June 2016. The first one is a Phase 1 pediatric study sponsored by Servier and conducted by University College London, UK in patients with acute lymphoblastic leukemia (ALL). The second one is a Phase 1 adult study sponsored by Servier and conducted by King’s College London, UK in patients with acute lymphoblastic leukemia (ALL).
2017: Submission of an IND Application for UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Cellectis submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to initiate Phase 1 clinical trials of UCART123 - the Company’s most advanced, wholly controlled TALEN® gene-edited product candidate in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Cellectis received in February 2017 an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to conduct Phase 1 clinical trials with UCART123 in patients with acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks the first allogeneic, “off-the-shelf” gene-edited CAR T-cell product candidate that the FDA has approved for clinical trials.
2018: Allogene assumed from Pfizer the global strategic collaboration agreement originally formed with Cellectis in 2014
Closing of a $175 million U.S. public offering
Submission of an IND Application for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)
Cellectis received in June 2018 an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to conduct Phase 1 clinical trials with UCART22, Cellectis’ second wholly controlled TALEN® gene-edited product candidate, for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) in adult patients.